Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to -$27.4 million.

  • Anaptysbio's Free Cash Flow fell 17030.12% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.3 million, marking a year-over-year decrease of 4055.75%. This contributed to the annual value of -$135.7 million for FY2024, which is 1158.49% down from last year.
  • Anaptysbio's Free Cash Flow amounted to -$27.4 million in Q3 2025, which was down 17030.12% from -$40.3 million recorded in Q2 2025.
  • Anaptysbio's 5-year Free Cash Flow high stood at $8.7 million for Q2 2021, and its period low was -$66.9 million during Q4 2024.
  • For the 5-year period, Anaptysbio's Free Cash Flow averaged around -$24.0 million, with its median value being -$24.2 million (2022).
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 14432.03% in 2021, then tumbled by 37755.5% in 2022.
  • Over the past 5 years, Anaptysbio's Free Cash Flow (Quarter) stood at -$25.3 million in 2021, then skyrocketed by 57.1% to -$10.9 million in 2022, then tumbled by 218.87% to -$34.6 million in 2023, then crashed by 93.29% to -$66.9 million in 2024, then surged by 59.11% to -$27.4 million in 2025.
  • Its last three reported values are -$27.4 million in Q3 2025, -$40.3 million for Q2 2025, and -$10.7 million during Q1 2025.